XBIT ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of XBiotech Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
Tuesday, XBiotech Inc XBIT announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.
XBiotech: Several Shots On Goal In Big Target Market Indications
XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis. While other biologics have targeted IL-1, none have been established to specifically target IL-1a.
